Abstract 495: Discovery of BPI-221351, a potent, selective, orally available, and brain penetrating dual inhibitor of mutant IDH1/2
Hongling Shen(Betta Pharmaceuticals (China)), Jia‐Bing Wang(United States Military Academy), Jing Guo(Qingdao University), Hong Lan(Betta Pharmaceuticals (China)), Hongfei Rong(Betta Pharmaceuticals (China)), Jiayu Zhao(Chengdu University of Information Technology), Haidi Shen(Betta Pharmaceuticals (China)), Jialin Ren(Betta Pharmaceuticals (China)), Xizhen Song(Betta Pharmaceuticals (China)), Zhengyao Zou(Betta Pharmaceuticals (China)), Lijia Liu(Ministry of Natural Resources), Xiaofeng Xu(Hangzhou Normal University), Yunting Bi(Betta Pharmaceuticals (China)), Jie Chen(Dana-Farber Cancer Institute), Haibo Chen(Shanghai University), Chao Wang(Xijing Hospital), Huijuan Zhang(East China University of Technology), Hong Chen(First People's Hospital of Chongqing), Xiaoyun Liu(Betta Pharmaceuticals (China)), Teng Ma(Florida A&M University - Florida State University College of Engineering), Yabin Li(Betta Pharmaceuticals (China)), Xiangyong Liu(Betta Pharmaceuticals (China)), Lieming Ding(Betta Pharmaceuticals (China)), Jun Tong(Hangzhou Normal University), Tong Xu(Inner Mongolia Normal University), Xuepeng Ju(Betta Pharmaceuticals (China))
Cited by 2
Related Papers
Cardiac Repair in a Porcine Model of Acute Myocardial Infarction with Human Induced Pluripotent Stem Cell-Derived Cardiovascular Cells
|Cell stem cell|2014|450
Adult IDH wild-type lower-grade gliomas should be further stratified
|Neuro-Oncology|2017|222
Effects of Filtration Seeding on Cell Density, Spatial Distribution, and Proliferation in Nonwoven Fibrous Matrices
|Biotechnology Progress|2001|190
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183